Spencer Group were delighted to attend the 17th edition of the Scrip Awards on the 2nd December, hosted live in London. The Scrip Awards honours the outstanding accomplishments of those improving human healthcare worldwide through their work in the pharmaceutical, biotech, and allied industries and as executive search specialists within Pharmaceutical Technology, Spencer Group enjoyed networking with experts in these fields.
Highlights within the award winners include the Innovation Award – won by Moderna’s mRNA vaccine technology, used in the sequence for mRNA-1273, one of the first vaccines developed to combat the global COVID-19 pandemic. Judges said, “This is truly a game changer in vaccine technology.”
The progress in technology has resulted in the emergence of microbial drug-resistant strains that have also affected the fight against infectious diseases such as pneumonia and malaria. With the vaccine market being expected to be valued at USD 69.86 billion in 2027 from USD 41.68 billion in 2019, registering a CAGR of 7.1% through the forecast period, according to a recent report by Emergen Research. Technology and the hiring of key individuals within this sector is pivotal to supporting the boost in the rise of the adoption in vaccines. This is exciting news for Spencer Group, as a leading recruitment specialist in this niche yet booming arena.
Other highlights of the awards night include CluePoints, BioNTech, and Pfizer’s Phase I/II/III study of SARS-COV-2 RNA vaccine BNT162b2 (Comirnaty) as well as Moderna’s Phase III COVE study of mRNA-1273 for COVID-19 prevention winning the award for the Clinical Advance of the Year – COVID-19 Pandemic Special Recognition Award, Sponsored by Parexel. Novel technology was taken to market at unprecedented speed, something our industry can certainly be proud of.
